The antigenic structure of the peplomer glycoprotein E2 of the porcine transmissible gastroenteritis coronavirus (TGEV) was explored using a panel of 23 hybridoma antibodies (MAbs). The topography of the epitopes was established by means of a competition radioimmunoassay. Four main antigenic sites, termed A, B, C and D, were thus clearly delineated. Most of the neutralization-mediating determinants were found to cluster in the A-B area, which has been shown to be highly conserved among TGEV strains. Cooperative enhancement of binding to sites B and D was observed following attachment of MAbs relevant to site A. Additional epitopes were identified on E2 by MAbs that selectively recognized its intracellular precursor.
INTRODUCTION
Transmissible gastroenteritis is an acute enteric disease of swine, most often fatal to newborn piglets (for review, see Bohl, 1975) . Its causative agent (TGEV) belongs to the Coronaviridae, a family of enveloped viruses possessing a single-stranded co-linear genome of positive polarity (for review, see Siddell et al., 1983) . The virions contain three functional classes of polypeptides: the nucleoprotein and two glycosylated proteins, namely a small transmembrane protein (El) and a large complex protein (called E2) which forms the characteristic surface projections. These peplomers have been shown to be responsible for attachment to cells, induction of neutralizing antibodies and cell fusion (Garwes et al., 1978/79; Hasony & Macnaughton, 1981 ; Holmes et al., 1981; Schmidt & Kenny, 1982; Collins et al., 1982; Vautherot et al., 1984) . Because these properties are essential in determining the virulence and tissue tropism of coronaviruses, studies have been recently undertaken to localize the biologically active sites of the protein with the help of monoclonal antibodies (MAbs).
Of the two polypeptides which have been shown to be associated with the peplomers of the avian infectious bronchitis coronavirus (IBV), only one (S1) was recognized by MAbs that neutralized infectivity of the virus (Mockett et al., 1984) . S 1 is encoded by the 5' terminal half of mRNA E (Binns et al., 1985) . Five antigenic sites have been identified on the peplomer protein of murine hepatitis coronavirus type 4 (MHV4, JHM strain). Three of them, including one of the three neutralization sites, were extensively conserved among MHV strains (Talbot et al., 1984; Talbot & Buchmeier, 1985) . Wege et al. (1984) have reported that those MAbs which immunoprecipitated both E2 (170K) and its reduced form gp98 (two co-migrating cleavage products of 98K) were neutralizing, whereas those directed selectively to gp98 revealed only weak neutralization. Only some of the epitopes present at the neutralization site were involved in cell fusion activity. Finally, four epitopes, all devoid of biological activity, were identified by MAbs which immunoprecipitated only gpl50 (intracellular precursor of E2).
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We have recently reported the derivation of MAbs directed against the three major structural polypeptides of TGEV and confirmed that all essential neutralization-mediating determinants were carried by the 220K glycoprotein E2 (Laude et al., 1986) . As was observed in the case of MHV4 (Wege et al., 1984) , all the 17 MAbs which recognized E2 also immunoprecipitated its intracellular precursor (E'2, 175K), whereas six other MAbs selectively recognized the 175K species. Unlike that of MHV4, the peplomer protein of TGEV remains uncleaved in the cell systems used, and is apparently devoid of cell fusion activity. We now report the results of a topological and functional analysis of antigenic sites present on this protein.
METHODS
Virus propagation and purification. The Purdue strain of TGEV was propagated in the pig kidney cell line PD5. A stock of 10 mg of purified virion was prepared as described elsewhere (Laude et al., 1986) , divided into aliquots, stored at -70 °C and used throughout the experiments.
Purification and labelling ofmonoctonal antibodies. The preparation of MAbs, as well as their characterization with respect to polypeptide specificity (E2 and/or E'2) and neutralizing ability have recently been published (Laude et al., 1986) . Immunoglobufins (Igs) from ascites fluids were purified by gel permeation as already described (Laude et al., 1986) , and stored at -20°C. The MAbs were tritiated by reductive methylation, a procedure which was expected to produce less modified lgGs than more frequently used labelling techniques such as iodination or biotinylation (Tack & Wilder, 1981) . IgGs were concentrated at about 8 to 10 mg/ml using a Minicon B 15 (Amicon) and concomitantly equilibrated in 0.2 M-borate buffer pH 8-9. The concentrated IgGs and the other reagents (0.05 M-NaOH, 0.4 M-formaldehyde) were preincubated for 1 h at 0 °C. Labelled potassium borohydride, KB3H4 (CEA, Gif-sur-Yvette, France; 64 Ci/mmol) was solubilized in NaOH at 1 mCi/p.l. Immediately afterwards, 5 ~tl of formaldehyde and 5 gl of KB3H4 were added to 100 p.l of IgG solution. The mixture was maintained for 15 rain at 0 °C, then unincorporated radioactivity was removed on a centrifuged column [1 ml Sephadex G-25 beads in phosphate-buffered saline (PBS); 1 rain at 1500 r.p.m.]. The specific activities of the MAb probes ranged from 1.5 x 105 to 5 × l0 s c.p.m./~tg. It was verified for each probe that mixing equal amounts of labelled and unlabelled IgGs in a self competition test (see below) resulted in a near 50 % binding.
Solid-phase competitive radioimmunoassay (RIA). Microtitre plates (Microelisa, Dynatech) were coated overnight with 1 ~tg purified virus per well in 50 p.1 50-mM-PIPES, 0-15 M-NaCI, pH 6-4. Coated wells were incubated for 1 h at 37 °C with 200 ~tl 1 ~ bovine serum albumin in PBS, then washed once in PBS containing 0-05 ~ Tween 20 (PBST). Two kinds of competition assay were performed. In the two-step (or sequential) test, the wells were incubated at 37 °C with 50 ~tl of serial fivefold dilutions of IgGs starting at 1 mg/ml. Two h later, the plates were washed once with PBST. Tritiated MAb diluted in PBS was added (4 x 104 to 8 x 104 c.p.m./well) and the plates were incubated for 2 h at 37 °C. In the single-step test, competitor MAb serial dilutions and tritiated MAbs were incubated together. The following steps were identical for both tests. After four washes with PBST, the MAbs bound to the wells were eluted in 2~ SDS and radioactivity was counted by liquid scintillation (Minaxi 4000, Packard). The results were expressed as a percentage of competition according to the formula: [(1 -c.p.m. bound with competitor MAb)/(c.p.m. bound without competitor MAb)] × 100. Each assay was done at least in duplicate. The maximal competitor/probe MAb ratio used ranged from 500 to 50.
Determination of antibody avidities. Saturation curves were obtained using the following RIA test. Antigencoated plates (500 ng of virus) received serial dilutions of 3H-labelled MAb in PBS, typically starting with 2-5 x 106 c.p.m, of input radioactivity. Background was measured for each dilution using uncoated wells. The data were plotted in a modified Scatchard form as described by Frankel & Gerhard (1979) .
Selection of antigenic variants. Twice plaque-purified clones of the Purdue strain were used as a virus source. MAb-containing ascites fluid was mixed with appropriate serial 10-fold dilutions of the virus in Eagle's MEM (final ascites fluid dilution 1/10), and which were allowed to incubate for 1 h at 37 °C. Replicate dilutions without MAb were incubated concomitantly. The infectivity of each suspension was measured by plaque formation on ST cell monolayers established in six-well trays, as described elsewhere (Laude, 1981) . Relevant ascites fluid was added (or not) at 1/100 dilution in the nutrient agar overlay. Two days later, well separated plaques on MAbcontaining plates were picked. Presumed variants were expanded in ascites fluid-containing medium (1 : 100), then screened for neutralization resistance. The mutagenized virus stocks used in some experiments were obtained by nitrous acid treatment (0.5 M, pH 4.2) as reported previously (Laude, 1981) . Infectivity decay was 1 loglo p.f.u./min; virus suspensions treated for 1 rain or for 1 to 4 min were used for selection against MAbs 12.18 and 51.t3 respectively. The variants were analysed in indirect immunofluorescence and neutralization assays following techniques described by Laude et al. (1986) .
RESULTS

Delineation of antigenic sites by competitive RIA
Competition immunoassays were performed on plates coated with purified TGEV, using 3H-labelled IgGs from each hybridoma, each MAb being tested in turn as a probe. The results of the first set of experiments using the ten most highly neutralizing MAbs in a sequential test (i.e. competitor MAb/wash/probe) are representatively shown in Fig. l (a) to (h). Most MAbs exerted a strong and reciprocal competition for binding against one or several other MAbs. Increasing the IgG concentration of MAb 12.18 led to stronger competition against MAbs 20.9 and 51.13 than shown here. This was correlated with the relatively low avidity of the former (see below). In addition, MAbs 40.1 and 76.2 displayed an exclusive but moderate two-way competition (not shown). This type of assay was then extended to the whole panel, including the seven remaining E2-E'2 MAbs and the six E'2 MAbs. All were weakly or non-neutralizing (i.e. neutralization index < 1 loglo at 10 p.g/ml, and limiting concentration/> 25 ~g/ml; data from Laude et al., 1986) . It was striking to note that most of these MAbs were poor competitors. In fact, they exhibited weak or no self-competition in our two-step procedure (not shown). This was imputed to a higher rate of release of bound antibodies than with the MAbs of the first group. A single-step procedure (i.e. competitor MAb dilutions and probe incubated together) was therefore carried out instead, although the sequential method gave more clear-cut results in our hands. As exemplified in Fig. 1 (/) to (/), cross-competition was observed within only two groups of these MAbs. No competition was detected when E'2 MAbs were used either as competitor or probe, except between two of them (31.191 and 4 
.3). E'2 MAbs thus recognized five different epitopes (not shown).
The results summarized in Table 1 clearly delineated four main groups among the E2-E'2 MAbs, designated A, B, C and D. A quite similar distribution of MAbs was obtained by considering as a criterion the amount of competitor MAb that resulted in 50~ inhibition of probe binding, instead of the level of competition reached at the plateau as done here. In contrast to antigenic sites C and D, sites A and B were defined by MAbs all of which markedly neutralized the virus. The latter two sites shared a common epitope, recognized by MAb 48.1.
Binding enhancement
Apart from the mutual blocking of MAb pairs, enhancement of MAb binding by a first MAb (i.e. negative competition) was frequently observed throughout this study. As can be seen in Fig.  2 , binding enhancement reached 50 to 100~ for a number of MAb pairs. Pairs of MAbs which induced >~ 30~o enhancement are designated by the letter E in Table 1 .
Relative avidity of MAbs
The avidity of each labelled MAb was compared in a binding assay using TGEV particles as antigen. The resulting Scatchard analyses are shown in Fig. 3 (a, b) and in Table 2 . With respect to their slopes, the regression lines were ordered roughly as expected from the respective position of the competition curves shown in Fig. 1 . Highly neutralizing MAbs did not greatly differ from the other MAbs with respect either to their avidity or to the maximum level of IgG bound. The anti-E'2 MAbs bound at almost the same level as the E2-E'2 MAbs. As illustrated by a typical set of saturation curves (Fig. 3c ), prior incubation with one of the MAbs defining site A augmented the fixation of MAb 76.2 up to the mean level, i.e. about 20 ng/well. The maximal amount of IgG bound was about 40 ng, which would mean approximately 55 ng protein E2 per well, i.e. 11% of the amount of virus added (500 ng). This is close to the proportion of protein E2 in the virion deduced from analysis of labelled material on polyacrylamide gels (unpublished result).
Derivation of neutralization-resistant ( NR) variants
In order to estimate the respective variability of the antigenic sites detected on protein E2 and eventually to construct a functional map, we produced a spectrum of antigenic variants, by selection against one each of the ten most neutralizing MAbs of our panel. independent variants of Purdue virus were obtained, each one being fully resistant to neutralization by the selector MAb (the NR variants are listed in Table 3 ). None of them reacted in an indirect immunofluorescence assay, excepting the 10.4-NR variants (not shown). These spontaneous variants were easily obtained, with a frequency ranging from 10 -5"1 to 10-6"5/wild-type p.f.u., except when the selector MAb belonged to group A. In fact, no spontaneous variant was derived using MAbs 12.18 and 51.13 of this group. However, 12 variants resistant to MAb 12.18 were obtained at a frequency of 10 -7.4 from mutagenized virus stocks. However, we failed to isolate even partially resistant variants to MAb 51.13 (frequency ~< 10-9), despite repeated attempts (changing virus stock or selector MAb concentration). Moreover, all the 12.18-NR variants had the phenotype of reduced plaque size (approx. twofold in diameter) as compared to wild-type, whereas all other variants had a standard plaque phenotype (Fig. 4b, c) . This was associated with a distinctly decreased production of infectious particles (Fig. 4a) . The 12.18-NR mutants were tested for possible thermosensitivity at 37 °C but with negative results (not shown). Identical findings were obtained with the ten 12.18-NR variants obtained using the D52.5 strain instead of the Purdue strain as a virus source.
Summary of competitive immunoassays with E2-E'2 MAbs
Linkages between antigenic variants
The neutralization resistance of each variant towards every selector MAb was measured. From the resulting reactivity pattern summarized in Table 3 , it appeared that (i) heterologous resistance was found in all classes of variants except in the 12.18-NR variants (not included in the Table) , (ii) only some of the co-resistances exhibited by variant pairs were reciprocal (25b. 21 and 8.8, 76.2 and 10.4, 40.1 and 10.4), (iii) most of the co-resistances arose with variant pairs whose selecting MAbs had been found to compete (bold characters in Table 3 ; one noticeable exception was those variants selected by 40.1 and 10.4), (iv) no co-resistance was observed towards any of the MAbs defining site A (51.13, 12.18, 48.1 and 20.9). Finally, examination of the reactivity of the variants by indirect immunofluorescence showed that their antigenicity was generally unaltered towards MAbs other than the selector MAb, with a unique case of total cross-unreactivity between variants selected by 25b. 21 or 8.8 (not shown). 
DISCUSSION
Hybridoma antibodies were used to realize a spatial and operational mapping of the antigenic determinants carried by the spike glycoprotein (E2, 220K) of TGEV. Topographical analysis by competitive binding assays is based on the assumption that positive competition will occur between a MAb pair if the relevant epitopes are at least partly overlapping or closely adjacent (Stone & Nowinski, 1980; YewdeU & Gerhard, 1982) . However, allosteric alteration of a distant epitope following attachment of the first MAb cannot be excluded. In addition, the quality of the MAb probe, any variation in antibody avidity, and the antigen-antibody dissociation rate would affect competitive binding. The construction of a physical map thus requires a careful examination of all these factors.
Thirteen out of the 17 available E2-E'2 MAbs fell into four competitive binding groups, A, B, C and D, and between individual members of each group the competition was generally strong and reciprocal (Fig. 1, Table 1 ). Moreover, it was noticed that the respective positions of homologous and heterologous competition curves were inverted for a number of MAb pairs, depending on which of them was used as the probe (see for example Fig. 1 d, g ). This would indicate that the lateral shift of the heterologous curve compared to the homologous one was essentially due to relative avidity, as expected in the case of true competition. Four epitopes, identified by MAbs 76.2, 44.4, 67.9 and 6. 179 mapped outside the major sites mentioned above. MAb 76.2 exerted a reciprocal, but partial and non-symmetrical competition with MAb 40.1 which recognizes site D (not shown). Hence, we suspect that this reflected a linkage related by conformation rather than a physical proximity of the relevant epitopes. MAbs 67.9 and 6.179 are the only E2-E'2 MAbs studied here which are completely devoid of neutralizing activity (Laude et al., 1986) .
Mapping was also performed with E'2 MAbs. This class of antibodies recognized specifically the 175K intracellular form of E2 and had no detectable neutralizing activity. They did not compete with any of the E2-E'2 MAbs, and delineated five epitopes scattered on the molecule (not shown). Similarly, Wege et al. (1984) identified at least four epitopes with their anti-gpl50 (precursor) MAbs. Less expected was the finding that the E'2 IgGs bound at nearly the same rate as E2-E'2 IgGs. We had previously speculated that a 175K minor protein found in purified virus particles might correspond to E'2 (Laude et al., 1986) . Even so, this seems unlikely to account for the binding of E'2 MAbs at such a level. We conclude that E'2 MAbs might react with determinants which are cryptic on E2 in its soluble form (immunoprecipitation test), but which either become accessible when E2 is incorporated into the virion, or are unmasked during the coating step of the assay (due most probably to attachment to plastic since the pH was optimally adjusted for virus infectivity). These E'2 determinants are probably masked as a consequence of additional glycosylation and/or folding of the polypeptide. As a complementary approach, mapping of functional sites was performed using a series of viral variants which fully escaped neutralization by a given MAb (Wiktor & Koprowski, 1980; Gerhard et al., 1981) . The ten most potent neutralizing MAbs of our panel were chosen as selector MAbs. Such an approach allows detection of epitopes that can be altered at the same time by a single mutation. Nevertheless, it must be borne in mind that one mutation giving rise to neutralization resistance may simultaneously affect distinct antigenic sites due to structural constraints. On the other hand, the selection may alter just one of the epitopes defining a given antigenic site (considering that a site may be composed of partially overlapping epitopes). At least for these reasons, the topographical and the functional approaches should not be expected to give fully superimposable maps. We found, however, that half of the functional linkages did correspond to a topographical linkage (Table 4) . Conversely, seven out of ten of the topographical linkages found within sites B, C and D had a functional counterpart. Concerning site A, it should be mentioned that spontaneous NR variants could be selected only using MAb 20.9. However, no (or little) functional linkage could be detected between any variants relevant to site A and other NR variants.
Taking our results as a whole, we would favour a model such as that presented in Fig. 5 (a) . In essence, TGE virion spikes would bear four major antigenic sites, despite the unusually large size of the protein (about 1200 amino acids). As an interesting feature, most of the determinants playing a crucial role in the neutralization of the virus cluster in a discrete area, apparently well isolated from the rest of the molecule. Neither topographical nor functional (i.e. neutralization co-resistance) linkages were observed between weakly or non-neutralizing MAbs and the seven MAbs delineating what we regard as the main neutralization-mediating domain. This domain is subdivided into two antigenic sites, designated A and B, which are related via a common Table 1. epitope, recognized by MAb 48.1. Both these sites were found to be strictly conserved among the different strains of TGEV tested (Laude et al., 1986) . Furthermore, there are indirect indications that the immunodominant sites of E2 could be located in the same domain, as polyclonal reagents from TGEV-infected swine essentially blocked binding to the epitopes of sites A and B (unpublished results). Part of site A might be of the utmost importance for the infectivity of TGEV. First, the 12.18-NR variants were obtained at a far lower frequency than other variants, even after mutagenesis. Moreover, all exhibited a reduced yield of infectious particles, whatever the strain of wild-type virus used (Purdue or D52.5). Second, no resistant mutant could be isolated using 51.13 as a selector MAb. Hence, we believe that some changes within site A may be lethal. We cannot, however, exclude the possibility that multiple mutation may be necessary to abolish antibody binding at that site. Subsidiary sites of neutralization were also identified. Sites C and D both combined with MAbs which altered the virus infectivity to quite a different extent. Only one of the four MAbs delineating site D was strongly neutralizing (MAb 40.1). Two MAbs directed to site C (3b. 5 and 10.4) gave paradoxical results according to the neutralization test used previously (Laude et al., 1986) . The finding that both exhibited aberrant Scatchard curves might be relevant (not shown). Site C may be subject to antigenic change, as well as minor sites of the molecule; indeed, the few natural variations detected among TGEV strains involved epitopes reacting with MAbs 3b. 5, 10.4, 76.2 and 67.9 (Laude et al., 1986) .
Our investigations also revealed the occurrence of cooperative effects between antibodies directed against distinct antigenic sites, leading to enhanced binding in the presence of a bound second MAb. This phenomenon has been reported for some other viral proteins (see Heinz et al., 1984 and references therein) . A model is presented in Fig. 5(b) which shows a complex (but apparently non-random) network of interactions between distant sites of E2. The putative conformational changes induced appear most often to be unidirectional. In addition, there are obvious preferred sites at which MAbs either cause binding enhancement or are easily enhanced. Attachment of MAbs 20.9, 12.18 or 51.13 induced an enhanced binding of many MAbs, suggesting that site A could be a major 'allosteric' site within E2. MAb 51.13 also augmented the binding of all E'2 MAbs (not shown). MAb 76.2 attachment was enhanced by every bound MAb relevant to sites A and B. This epitope might be partly buried in the molecule, since prior addition of one of the latter MAbs augumented the amount of MAb 76.2 bound up to the average level (Fig. 3 c) . Site C appeared rather stable compared to the others. Finally, it should be pointed out that both binding enhancement and neutralization co-resistance were never observed (except in one case) for the same pair of epitopes (Table 4) , which further adds significance to the model presented.
This study could also provide some clues towards a better understanding of the mechanism of neutralization of coronaviruses. First, we would emphasize the fact that all the MAbs that induced marked binding enhancement recognized epitopes mapped into the major neutralization domain, especially into site A. This adds one more piece to the body of information which indicates that viral inactivation may result from a conformational change of a specific protein (see Dimmock, 1984 , for references). Second, we observed during the competition experiments that the MAbs roughly fell into two categories: most of the weakly or nonneutralizing MAbs failed to exert a clear-cut self-competition in the sequential test, in contrast to those MAbs which markedly impaired the infectivity of the virus. Not surprisingly, this was independent of their apparent avidity, and would rather reflect the marked discrepancies in the rate of release of the bound antibodies. Accordingly, the stability of binding between an antibody and a critical determinant might be concerned with the neutralization process. Moreover, a conformational rearrangement of the target protein might be one way to achieve an increased stabilization of the complex. Further investigation including a larger panel of both classes of anti-E2 MAbs is required, however, to confirm our observation.
In conclusion, the information provided here may have important implications for the development of a synthetic or genetically engineered vaccine against TGEV. Our data support the idea that an artificial protective antigen may include epitopes of area A-B, which is closely involved in virus neutralization, extensively conserved among the strains and potentially immunodominant. Studies are in progress to analyse the antigenic reactivity towards the relevant E2 MAbs of fragments generated by partial proteolysis, with the aim of orienting the available schematic map on the physical structure of the protein.
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